Newer Blood Thinner May Pose Danger to Trauma
WEDNESDAY, Nov. 23 (HealthDay News) -- A new blood thinner
touted for its convenience and enhanced quality of life may have
hidden problems that could threaten the lives of certain patients,
a new report suggests.
A letter to the editor in the Nov. 24 issue of the
New England Journal of Medicine reports severe bleeding
complications among trauma patients on the anti-clotting medicine
Pradaxa (dabigatran etexilate).
In one case, a patient died, the letter said.
"We have noted on multiple occasions patients who have 'bleeding out' from Pradaxa and our hands are tied," said Dr. Bryan Cotton, lead letter author and a trauma surgeon with the University of Texas Health Science Center at Memorial Hermann Hospital in Houston. "They're bleeding out all over and there's absolutely nothing we can do about it . . . I'm helpless and hopeless when it comes into my emergency room."
The main problem, Cotton said, is that there's no real way to
reverse the anti-clotting effect of the drug, unlike older agents
such as warfarin.
According to the letter, the only way to reverse Pradaxa is with
emergency dialysis but, said Cotton, "in a patient bleeding to
death, that's not really a practical or pragmatic option."
Warfarin (Coumadin, Jantoven) has been the mainstay of
blood-thinning medications to manage heart and stroke patients for
But the drug is notoriously difficult to manage, requiring
frequent lab tests and having interactions with multiple foods and
other medications. Its one big advantage, however, is that its
blood-thinning properties are easily reversible when needed.
Enter the new, easier-to-use blood thinner, Pradaxa, first
approved by the U.S. Food and Drug Administration in late 2010 for
use in patients with atrial fibrillation, a common and dangerous
form of irregular heartbeat.
"There is an advantage over warfarin in many ways because of the simplicity and ease of management," said Dr. Jack Ansell, chairman of the department of medicine at Lenox Hill Hospital in New York City. "There are very little interactions with other drugs or foods, but once again, warfarin is relatively easily reversible."
Pradaxa also has other problems in addition to the
irreversibility, the letter said, namely that there are no readily
available tests to assess how well it's working or not working.
"You can't really check the labs. There's no easy, cheap, readily available lab test," Cotton noted.
The information provided in the letter, said Dr. Lisandro
Irizarry, chair of emergency medicine at the Brooklyn Hospital
Center in New York City, is "incredibly useful and incredibly
"Although this medication provides enhanced quality of life, it does have a significant impact on how we manage patients because there's no way to reverse it and no way to measure how thin the blood is," he said.
Cotton and his co-authors urged the U.S. Food and Drug
Administration (FDA) to support more trials to assess the
potentially wide-ranging effects of the drug.
"We absolutely understand that it's a lot better for patients from a convenience standpoint . . . but when something goes wrong, it can go wrong very badly," Cotton said.
In a statement, Pradaxa's maker, Boehringer Ingelheim, confirmed
that, "At this time, there is no reversal agent available" for the
blood thinner. The company says that dialysis can lead to "the
removal of about 60 percent of the drug over two to three hours;
however, data supporting this approach are limited."
In the meantime, "Patient safety is our top priority and we
frequently communicate with the FDA and regulatory agencies around
the world to ensure they have the most up-to-date information
regarding the safety profile of Pradaxa," the company said. "All
treatment decisions should be made on an individual basis between
patients and their health care providers and should take into
consideration the overall benefits and risks associated with
various treatment options."
Pradaxa is not the only new-generation blood thinner to be
approved recently -- the anti-clotting drug Brilinta (ticagrelor)
gained FDA approval for use in heart patients in July. However,
according to Ansell, there is no "reversability" problem with
U.S. National Library of Medicine has more on
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.